BIAL announced today that the medicinal product ONGENTYS® (opicapone) for the treatment of adult Parkinson´s disease patients with motor fluctuations was approved by the European Commission. BIAL will make ONGENTYS® available for Parkinson’s disease patients across Europe in 2016 and 2017.

ONGENTYS® is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations.

Professor Heinz Reichmann, Professor and Chair Department of Neurology and Dean of Medical Faculty at the University of Dresden said, “Opicapone is a new option to treat patients with motor complications with the convenience of once-daily dosing. It may become the treatment of choice when levodopa-treated patients need additional help to improve motor symptoms such as wearing off in Parkinson´s disease.”

It’s always good news when a new Parkinson’s treatment makes it through the clinical trial and regulatory process

Tom Isaacs, President and Co-founder, The Cure Parkinson's Trust

Tom added, "There have been very few novel therapies which have been developed for this condition over the past 25 years. The fact that Bial have launched opicapone as a symptomatic treatment to extend the period that people with Parkinson’s can benefit from their L-dopa medication is indicative of a new wave of treatments and the renewed interest of pharmaceutical companies in the Parkinson’s sector.”

In full - Bial 'Opicapone' press article